Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies

References

• Shaw JP, Cundy KS. Biological screens of PMEA prodrugs. Pharm Res 1993; 10: 294–299.
   PubMedGoogle Scholar
• Lee WA, Martin JC. (2006). Perspectives on the development of acyclic nucleotide analogs as antiviral drugs. Antiviral Res, 71:254–259.
   PubMed Web of Science ®Google Scholar
• Gupta S, Chavhan S, Sawant K. Self nanoemulsifying drug delivery system of adefovir dipivoxil: Design, characterization, in vitro and ex vivo evaluation. Colloids Surf A Physicochem Engg Asp 2011; 392: 145–155.
   Web of Science ®Google Scholar
• Noble S, Faulds D. (1996). Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs, 52:93–112.
   PubMed Web of Science ®Google Scholar
• Palú G, Stefanelli S, Rassu M, Parolin C, Balzarini J, De Clercq E. (1991). Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antiviral Res, 16:115–119.
   PubMed Web of Science ®Google Scholar
• Available at: www.emea.europa.eu. Accessed March 2011.
   Google Scholar
• Shaw JP, Louie MS, Krishnamurthy VV, Arimilli MN, Jones RJ, Bidgood AM et al. (1997). Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab Dispos, 25:362–366.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Fishback JA, Shaw JP, Lee ML, Soike KF, Visor GC et al. (1994). Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm Res, 11:839–843.
   PubMed Web of Science ®Google Scholar
• Gulati M, Grover M, Singh S, Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm 1998; 165:129–168.
   Web of Science ®Google Scholar
• Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release, 133:238–244.
   PubMed Web of Science ®Google Scholar
• Shah M, Chuttani K, Mishra AK, Pathak K. (2011). Oral solid compritol 888 ATO nanosuspension of simvastatin: optimization and biodistribution studies. Drug Dev Ind Pharm, 37:526–537.
   PubMed Web of Science ®Google Scholar
• Taburet AM, Paci-Bonaventure S, Peytavin G, Molina JM. (2003). Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapies. Clin Pharmacokinet, 42:1179–1191.
   PubMed Web of Science ®Google Scholar
• Triplett MD, Rathman JF. Optimization of b-carotene loaded solid lipid nanoparticle preparation using a high shear homogenization technique. J Nanopart Res 2009; 11; 601–614.
   Web of Science ®Google Scholar
• Muhler AZ, Mehnert W. Drug release & release mechanism of Prednisolone loaded SLN. Pharmazie 1998; 53:552–559.
   Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
   PubMed Web of Science ®Google Scholar
• Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785–796.
   PubMed Web of Science ®Google Scholar
• Wong SM, Kellaway IW, Murdan S. (2006). Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm, 317:61–68.
   PubMed Web of Science ®Google Scholar
• Date AA, Kulkarni RM, Patravale VB. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004; 56: 827–840.
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M et al. (2007). Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int J Pharm, 338:198–206.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing–oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631–644.
   PubMed Web of Science ®Google Scholar
• Heng D, Ogawa K, Cutler D, Chan H, Raper J. Pure drug nanoparticles in tablets: what are the dissolution limitations? J Nanopart Res 2010; 12:1743–1754.
   Web of Science ®Google Scholar
• Schubert MA, Müller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles–evaluation of the method and process parameters. Eur J Pharm Biopharm, 55:125–131.
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Cundy KC, Bishop JF, Czekai DA. Surface modified drug nanoparticles. US Patent 5,145,684; 1992.
   Google Scholar
• Pardeike J, Müller RH. (2010). Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. Int J Pharm, 391:322–329.
   PubMed Web of Science ®Google Scholar
• Ghosh MN. Fundamentals of experimental pharmacology. Indian J Pharmacol 2007; 39: 216–219.
   Google Scholar
• Arulsudar N, Subramanian N, Mishra P, Sharma RK, Murthy RS. (2003). Preparation, characterisation and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine. J Drug Target, 11:187–196.
   PubMed Web of Science ®Google Scholar
• Wu MS, Robbins JC, Bugianesi RL, Ponpipom MM, Shen TY. (1981). Modified in vivo behavior of liposomes containing synthetic glycolipids. Biochim Biophys Acta, 674:19–29.
   PubMed Web of Science ®Google Scholar
• Shin SC, Bum JP, Choi JS. (2000). Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. Int J Pharm, 209:37–43.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release, 107:215–228.
   PubMed Web of Science ®Google Scholar
• Jacobs C, Müller RH. (2002). Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res, 19:189–194.
   PubMed Web of Science ®Google Scholar
• Freitas C, Müller RH. (1999). Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 47:125–132.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Kaneniwa N. (1986). Effect of seed crystals on solid-state transformation of polymorphs of chloramphenicol palmitate during grinding. J Pharm Sci, 75:506–511.
   PubMed Web of Science ®Google Scholar
• Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci, 13:123–133.
   PubMed Web of Science ®Google Scholar
• Irache G, Poncela J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998; 34: 191–219.
   PubMed Web of Science ®Google Scholar
• Mathot F, van Beijsterveldt L, Préat V, Brewster M, Ariën A. (2006). Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Control Release, 111:47–55.
   PubMed Web of Science ®Google Scholar